ArticleDatabase : the journal of biological databases and curation2025
CancerPPD2: an updated repository of anticancer peptides and proteins.
Article in Database : the journal of biological databases and curation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Dynamic Fourier wavelet positional encoding for anticancer peptide prediction via transfer learning.iScience · 2026Article
- Dual Activity Microbial Peptides Catalog.Scientific data · 2026Article
- The Snakin Family of Antimicrobial Peptides: Promising Alternatives to Conventional Antibiotics.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Contemporary data-driven innovations in peptide-based therapeutic design.Briefings in bioinformatics · 2026Review
- Article
- Exploring and expanding the chemical multiverse of peptides.Chemical science · 2026Review
- Comparative analysis of tissue-specific anticancer peptide prediction models: ACP-Boost framework.Frontiers in molecular biosciences · 2026Article
- MetaPepticon: automated prediction of anticancer peptides from microbial genomes and metagenomes.PeerJ · 2026Article
- Design of synthetic selenopeptides with antioxidant activity for the treatment of XP and non-melanoma skin cancer.Frontiers in systems biology · 2026Article
- AttBiLSTM_DE: enhancing anticancer peptide prediction using word embedding and an optimized attention-based BiLSTM framework.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
CancerPPD2 (http://webs.iiitd.edu.in/raghava/cancerppd2/) is an updated version of CancerPPD, developed to maintain comprehensive information about anticancer peptides and proteins. It contains 6521 entries, each entry provides detailed information about an anticancer peptide/protein that include origin of the peptide, cancer cell line, type of cancer, peptide sequence, and structure. These anticancer peptides have been tested against 392 types of cancer cell lines and 28 types of cancer-associated tissues. In addition to natural anticancer peptides, CancerPPD2 contains 781 entries for chemically modified and 3018 entries for N-/C- terminus modified anticancer peptides. Few entries are also linked with 47 clinical studies and have provided the cross reference to Uniprot, DrugBank, and ThPDB2. The possible entries also linked with clinical trials. On average, CancerPPD2 contains around 85% more information than its previous version, CancerPPD. The structures of these anticancer peptides and proteins were either obtained from the Protein Data Bank (PDB) or predicted using PEPstrMOD, I-TASSER, and AlphaFold. A wide range of tools have been integrated into CancerPPD2 for data retrieval and similarity searches. Additionally, we integrated a REST API into this repository to facilitate automatic data retrieval via program. Database URL: https://webs.iiitd.edu.in/raghava/cancerppd2/api/rest.html.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.